Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Thermosensitive Folic Acid-Targeted Poly (Ethylene-Co-Vinyl Alcohol) Hemisuccinate Polymeric Nanoparticles for Delivery of Epirubicin to Breast Cancer Cells Publisher

Summary: Scientists developed heat-sensitive nanoparticles that release breast cancer drugs more effectively at higher temps. #CancerResearch #Nanomedicine

Hassanzadeh F1 ; Maaleki S2 ; Varshosaz J3 ; Khodarahmi GA2 ; Farzan M2 ; Rostami M1
Authors

Source: Iranian Polymer Journal (English Edition) Published:2016


Abstract

A novel thermosensitive folic acid (FA)-targeted succinylated poly (ethylene-co-vinyl alcohol) (EVOH) (EVOHS-FA) nanocarrier was synthesized for the specific delivery of epirubicin (EPI) to MCF-7 breast cancer cell line. Three different ratios of synthesized EVOH-Suc were reacted with FA. The structure of the desired products (EVOHS40-FA, EVOHS60-FA and EVOHS80-FA) was confirmed by 1H NMR and FTIR techniques. Nanoparticles were obtained by nano-precipitation procedure using DMSO/H2O as solvent/anti-solvent. The particle size, zeta potential, entrapment efficacy and in vitro release profile of the final formulations in different temperatures were measured. The optimized nanoparticles had the particle size of 214 ± 8.5 nm, zeta potential of −29.6 mV, PDI of 0.198 ± 0.04, and a high encapsulation efficiency that released the drug efficiently within 450 h at the temperature of 40 °C compared to 37 °C. The morphology of nanoparticles was studied by scanning electron microscopy. The in vitro cytotoxicity was evaluated using the MTT assay on MCF-7 cell lines in response to temperatures of 37 and 40 °C. The MTT assay indicated that the targeted nanoparticles carrying EPI were significantly more cytotoxic than the non-targeted nanoparticles and the free drug at 40 °C. © 2016, Iran Polymer and Petrochemical Institute.
Other Related Docs
10. Plga-Peg-Ra-Based Polymeric Micelles for Tumor Targeted Delivery of Irinotecan, Pharmaceutical Development and Technology (2018)